1. Home
  2. ACRS vs AOUT Comparison

ACRS vs AOUT Comparison

Compare ACRS & AOUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACRS
  • AOUT
  • Stock Information
  • Founded
  • ACRS 2012
  • AOUT 2020
  • Country
  • ACRS United States
  • AOUT United States
  • Employees
  • ACRS N/A
  • AOUT N/A
  • Industry
  • ACRS Biotechnology: Pharmaceutical Preparations
  • AOUT Ordnance And Accessories
  • Sector
  • ACRS Health Care
  • AOUT Industrials
  • Exchange
  • ACRS Nasdaq
  • AOUT Nasdaq
  • Market Cap
  • ACRS 165.7M
  • AOUT 133.2M
  • IPO Year
  • ACRS 2015
  • AOUT N/A
  • Fundamental
  • Price
  • ACRS $1.95
  • AOUT $8.81
  • Analyst Decision
  • ACRS Strong Buy
  • AOUT Strong Buy
  • Analyst Count
  • ACRS 9
  • AOUT 2
  • Target Price
  • ACRS $9.25
  • AOUT $15.00
  • AVG Volume (30 Days)
  • ACRS 891.2K
  • AOUT 78.4K
  • Earning Date
  • ACRS 11-05-2025
  • AOUT 09-04-2025
  • Dividend Yield
  • ACRS N/A
  • AOUT N/A
  • EPS Growth
  • ACRS N/A
  • AOUT N/A
  • EPS
  • ACRS N/A
  • AOUT N/A
  • Revenue
  • ACRS $16,789,000.00
  • AOUT $210,381,000.00
  • Revenue This Year
  • ACRS N/A
  • AOUT N/A
  • Revenue Next Year
  • ACRS N/A
  • AOUT $7.08
  • P/E Ratio
  • ACRS N/A
  • AOUT N/A
  • Revenue Growth
  • ACRS N/A
  • AOUT 5.56
  • 52 Week Low
  • ACRS $1.05
  • AOUT $8.10
  • 52 Week High
  • ACRS $5.17
  • AOUT $17.91
  • Technical
  • Relative Strength Index (RSI)
  • ACRS 56.76
  • AOUT 39.86
  • Support Level
  • ACRS $2.01
  • AOUT $8.15
  • Resistance Level
  • ACRS $2.16
  • AOUT $10.50
  • Average True Range (ATR)
  • ACRS 0.10
  • AOUT 0.38
  • MACD
  • ACRS -0.01
  • AOUT -0.15
  • Stochastic Oscillator
  • ACRS 47.44
  • AOUT 27.52

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

About AOUT American Outdoor Brands Inc.

American Outdoor Brands Inc is engaged in the business of providing outdoor products and accessories for hunting, fishing, camping, shooting, and personal security and defense products. The company designs and produces products and accessories, including shooting supplies, rest, vaults, and other related accessories; premium sportsman knives and tools for fishing and hunting; land management tools for hunting preparedness; harvesting products for post-hunt or post-fishing activities; electro-optical devices, including hunting optics, firearm aiming devices, flashlights, and laser grips; reloading, gunsmithing, and firearm cleaning supplies; and survival, camping, and emergency preparedness products.

Share on Social Networks: